Ipilimumab and craniotomy in patients with melanoma and brain metastases: A case series

Neurosurgical Focus

Volumn 38, Issue 3, 2015, Pages

  Jones, Pamela S ^a   Cahill, Daniel P ^a   Brastianos, Priscilla K ^a   Flaherty, Keith T ^a   Curry, William T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Craniotomy; Immunotherapy; Ipilimumab; Melanoma; Metastases

Indexed keywords

IMMUNOLOGIC FACTOR; IPILIMUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; BRAIN NEOPLASMS; CRANIOTOMY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MELANOMA; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CRANIOTOMY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84929620586     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.12.FOCUS14698     Document Type: Article

References (27)

1. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22:2101-2107, 2004.
2. Amin A, DePril V, Hamid O, Wolchok J, Maio M, Neyns B, et al: Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol 27 (15 Suppl):9037, 2009 (Abstract).
3. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD: Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 19:1009-1020, 2013.
4. Balakan O, Süner A, Yiğiter R, Balakan T, Sirikçi A, Sevinç A: Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Intern Med 51:2819-2823, 2012.
5. Brastianos PK, Curry WT, Oh KS: Clinical discussion and review of the management of brain metastases. J Natl Compr Canc Netw 11:1153-1164, 2013.
6. Callahan MK, Wolchok JD, Allison JP: Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37:473-484, 2010.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011.
8. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, et al: Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106:2729-2734, 2009.
9. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, et al: Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an openlabel, single-arm phase 2 trial. Lancet Oncol 13:879-886, 2012.
10. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al: Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 62:1021-1028, 2013.
11. Feldmann G, Brossart P, Zipfel M, von Lilienfeld-Toal M: Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature. Case Rep Oncol 6:229-235, 2013.
12. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al: Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293-1300, 2004.
13. Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, et al: Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 28:1140-1144, 2011.
14. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010.
15. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, et al: CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5:557-561, 2008.
16. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al: Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116:1767-1775, 2010.
17. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al: CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105:14987-14992, 2008.
18. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR: Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33:665-680, 2007.
19. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459-465, 2012.
20. McWilliams RR, Brown PD, Buckner JC, Link MJ, Markovic SN: Treatment of brain metastases from melanoma. Mayo Clin Proc 78:1529-1536, 2003.
21. Peggs KS, Quezada SA, Korman AJ, Allison JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206-213, 2006.
22. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11-20, 1998.
23. Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, et al: Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 20:247-250, 2010.
24. Simeone E, Gentilcore G, Romano A, Daponte A, Caraco C, Grimaldi AM, et al: Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. J Clin Oncol 30 (Suppl): 8573, 2012 (Abstract).
25. Tarhini AA, Agarwala SS: Management of brain metastases in patients with melanoma. Curr Opin Oncol 16:161-166, 2004.
26. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ: Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530-534, 2011.
27. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009.